Page last updated: 2024-12-05

1-naphthol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Naphthol, also known as α-naphthol, is an organic compound with the formula C10H7OH. It is a white solid that is poorly soluble in water but soluble in most organic solvents. 1-Naphthol is an important intermediate in the synthesis of many dyes, pharmaceuticals, and other chemicals. It can be synthesized by the sulfonation of naphthalene followed by alkali fusion. 1-Naphthol has various applications, including as a reagent in organic synthesis, a precursor to other chemicals, and a component of certain dyes and pigments. It exhibits antioxidant properties and has been studied for its potential biological activity. 1-Naphthol is also used in the production of polymers and resins. Research on 1-naphthol focuses on its potential applications in various fields, including organic synthesis, materials science, and medicinal chemistry.'

1-naphthol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-naphthol : A naphthol carrying a hydroxy group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

hydroxynaphthalene : Any member of the class of naphthalenes that is naphthalene carrying one or more hydroxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7005
CHEMBL ID122617
CHEBI ID10319
SCHEMBL ID3416
MeSH IDM0093636

Synonyms (123)

Synonym
1np ,
AB-131/40232333 ,
SGCUT00118 ,
LS-95401 ,
nsc 9586
ci 76605
ci oxidation base 33
einecs 201-969-4
ccris 1172
ai3-00106
hsdb 2650
tertral ern
nsc-9586
basf ursol ern
1-hydroxynaphthalene
furro er
.alpha.-naphthol
ursol ern
durafur developer d
fouramine ern
zoba ern
1-naphthalenol
nsc9586
fourrine 99
c.i. 76605
wln: l66j bq
.alpha.-hydroxynaphthalene
fourrine ern
c.i. oxidation base 33
nako trb
CHEBI:10319 ,
naphthalen-1-ol
alpha-hydroxynaphthalene
inchi=1/c10h8o/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11
NCHEMBIO791-COMP4 ,
1-naphthol
alpha-naphthol
90-15-3
C11714 ,
naphthol ,
TO_000072 ,
N2780_SIAL ,
1-naphthol, bioxtra, >=99%
N1000_SIAL ,
1-naphthol, reagentplus(r), >=99%
chembl122617 ,
naphth-1-ol, 9
bdbm23450
st5214429
zinc00967929
70442_fluka
alpha-naphthol, 1-naphthol
35825_riedel
70438_fluka
33420_riedel
50356-21-3
1-naphthol, >=98.0% (gc)
1-naphthol, puriss. p.a., reag. ph. eur., >=99% (gc)
N0864
hydroxynaphthalene
AKOS000118822
N0026
A843458
NCGC00249169-01
naphthalenol
1321-67-1
dtxsid6021793 ,
NCGC00256563-01
dtxcid401793
cas-90-15-3
tox21_302768
tox21_202120
NCGC00259669-01
BBL011611
STL163337
unii-2a71eaq389
2a71eaq389 ,
FT-0608111
4B33
naphthol, 1-
duloxetine hydrochloride impurity d [ep impurity]
duloxetine impurity d [usp impurity]
duloxetine impurity d
1-naphthol [inci]
1-naphthol [mi]
1-naphtol-
1-naphthol [hsdb]
SCHEMBL3416
naphthyl-1-ol
alpha-naphthyl alcohol
naphthol-1
(+)-naphthol
alpha-napthol
1-napthol
1-naphtol
8 -naphthol
napthalenol
1-naphthyl alcohol
napthyl alcohol
hydroxy naphthalene
naphthalene-1-ol
naphthol 1
J-610055
mfcd00003930
F1908-0108
1-naphthol, certified reference material, tracecert(r)
1-naphthol, puriss., for fluorescence, >=99.0% (gc)
GS-6917
1-naphthol, saj special grade, >=99.0%
1-naphthol, pestanal(r), analytical standard
1-naphthol, lr, >=99%
1-naphthol, pure pa, 99%
1-naphthol, p.a., 99.0%
1-naphthol, vetec(tm) reagent grade, 98%
CS-W020125
HY-Y1309
Q408876
1-naphthol; 1-naphthalenol; 1-hydroxynaphthalene; 1-naphthyl alcohol; hydroxynaphthalene
1-naphthol, reagent
1-naphthol, purified
EN300-19501
duloxetine ep impurity d (1-naphthol)
Z104474036

Research Excerpts

Toxicity

1-Naphthol was selectively toxic to human colorectal tumours compared to corresponding normal colonic tissue removed at surgery and maintained in short-term organ culture.

ExcerptReferenceRelevance
"The short-term toxic effects of both sublethal and lethal concentrations of 1-naphthol were studied by light microscopy examination of the digestive gland-gonad complex of the common periwinkle Littorina littorea."( Short-term toxic effects of 1-naphthol on the digestive gland-gonad complex of the marine prosobranch Littorina littorea (L): a light microscopic study.
Angulo, E; Cajaraville, MP; Marigómez, JA,
)
0.65
"1-Naphthol was selectively toxic to human colorectal tumours compared to corresponding normal colonic tissue removed at surgery and maintained in short-term organ culture."( Selective toxicity of 1-naphthol to human colorectal tumour tissue.
Cohen, GM; d'Arcy Doherty, M; Wilson, GD, 1985
)
2.03
" These results suggest that a gender-specific 1,4-naphthoquinone metabolic pathway may exist, which gives rise to unknown toxic metabolites."( In vitro toxicity of naphthalene, 1-naphthol, 2-naphthol and 1,4-naphthoquinone on human CFU-GM from female and male cord blood donors.
Croera, C; Ferrario, D; Gribaldo, L, 2008
)
0.63

Bioavailability

ExcerptReferenceRelevance
" After oral dosing, peak plasma concentrations of 1-naphthol occurred at 1 hr; parent compound made up less than 15% of the total radioactivity, and the bioavailability was 32%."( Disposition of 1-naphthol in the channel catfish (Ictalurus punctatus).
Plakas, SM; Stehly, GR,
)
0.74
" The rate of absorption of alpha-NA in the presence of these polyphenols also varied."( Dietary polyphenols (-)-epicatechin and chrysin inhibit intestinal glucuronidation metabolism to increase drug absorption.
Awazu, S; Mizuma, T, 2004
)
0.32
"Presystemic intestinal metabolism reduces the intestinal absorption and bioavailability of orally administered drugs."( Factors affecting glucuronidation activity in Caco-2 cells.
Haga, M; Hayashi, M; Mizuma, T; Momota, R, 2004
)
0.32
" Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy."( Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Juvonen, RO; Poso, A; Rahnasto, M; Raunio, H; Wittekindt, C, 2005
)
0.33
" This in turn may affect the bioavailability of therapeutic drugs and toxicity levels of environmental chemicals, particularly procarcinogens."( Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells.
Naganuma, M; Okamura, S; Saruwatari, A; Tamura, H, 2006
)
0.59

Dosage Studied

ExcerptRelevanceReference
"5 g/kg body weight) and 30-day repeat dosing (200, 100 and 50 mg/kg body weight) studies."( 1-Naphthol--single and repeated dose (30-day) oral toxicity studies in the mouse.
Buckley, P; Poole, A, 1989
)
1.72
" A significant increase in life span was observed in EATC but not in L1210 bearing mice dosed with 1-naphthol (50-60 mg/kg)."( Antitumour activity of 1-naphthol against L1210 leukaemia in vivo and Ehrlich ascites tumour cells in vivo and in vitro.
Cohen, GM; d'Arcy Doherty, M; Jones, M, 1986
)
0.8
" These samples were collected just before each dosage of bepridil."( An LC method for quantifying bepridil in human plasma using 1-naphthol as the internal standard.
Goto, Y; Itoh, K; Iwai, S; Katoh, N; Kobayashi, M; Kuronuma, H; Narayama, Y; Noda, K; Tadano, K, 2011
)
0.61
" Hemolytic anemia was also found in G6PD-deficient mice at this dosage of naphthalene."( Development of a novel mouse model of severe glucose-6-phosphate dehydrogenase (G6PD)-deficiency for in vitro and in vivo assessment of hemolytic toxicity to red blood cells.
Fok, TF; Fung, KP; Gu, GJ; James, AE; Ko, CH; Li, CL; Li, K; Ng, PC; Wong, RP, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
genotoxinA role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
naphtholA member of the class of naphthols carrying a single hydroxy substituent at C-1 or C-2. A closed class.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Phenolic Malonylglucosides Biosynthesis213
phenolic malonylglucosides biosynthesis210
alkylnitronates degradation350

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency64.91590.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency61.13060.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency11.88290.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency33.69490.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency28.02960.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency59.22990.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency35.65330.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency42.62060.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency70.40720.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency22.44100.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency62.44500.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.04740.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency56.36910.001019.414170.9645AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency19.23640.000723.06741,258.9301AID743085; AID743122
Histone H2A.xCricetulus griseus (Chinese hamster)Potency111.17100.039147.5451146.8240AID1224845; AID1224896
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.24920.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency20.29160.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency20.29160.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)2.00000.00051.41288.2000AID160706
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)2.00000.00050.57393.4000AID160706
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)3.20000.00011.774010.0000AID241334
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)130.00850.00443.889510.0000AID241172; AID420671
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)3.60000.00462.018210.0000AID6790
Cytochrome P450 2A5Mus musculus (house mouse)IC50 (µMol)139.97951.00004.20259.7051AID241174; AID420670
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)260.00000.30003.25807.3000AID1222388; AID1222389
MAP kinase-activated protein kinase 2Homo sapiens (human)IC50 (µMol)100.00000.00201.16206.0000AID390576
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
toll-like receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
leukotriene metabolic processMAP kinase-activated protein kinase 2Homo sapiens (human)
inflammatory responseMAP kinase-activated protein kinase 2Homo sapiens (human)
DNA damage responseMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
response to lipopolysaccharideMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of interleukin-6 productionMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
response to cytokineMAP kinase-activated protein kinase 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMAP kinase-activated protein kinase 2Homo sapiens (human)
p38MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of mRNA stabilityMAP kinase-activated protein kinase 2Homo sapiens (human)
macropinocytosisMAP kinase-activated protein kinase 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
inner ear developmentMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionMAP kinase-activated protein kinase 2Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of cellular response to heatMAP kinase-activated protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-activated protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
centrosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 2Homo sapiens (human)
extracellular exosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID133223Percentage inhibition of the mouse arachidonic acid induced ear edema assay (AA) at a dose of 100 ug/ear1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
AID636078Cytotoxicity against CHO cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1390975Inhibition of Mycobacterium tuberculosis IMPDH deltaCBS mutant assessed as reduction in NADH production at 1 mM using IMP as substrate preincubated for 5 mins followed by substrate addition measured for 32 mins in presence of NAD+2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID241172Inhibitory concentration against human cytochrome P450 2A62005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID160706In vitro inhibition of Prostaglandin G/H synthase in BSV cell line.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1222388Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1182519Radioprotective activity against gamma-irradiated human MOLT4 cells preincubated for 1 hr at 100 to 400 uM before gamma-irradiation measured after 18 hrs by erythrosine B dye-exclusion test2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Design and synthesis of 8-hydroxyquinoline-based radioprotective agents.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID513046Inhibition of Caenorhabditis elegans CED-3-mediated apoptosis assessed as [35]S methionine labeled CED-9 cleavage product at 100 uM after 2 hrs by fluorescence assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
The nongenotoxic carcinogens naphthalene and para-dichlorobenzene suppress apoptosis in Caenorhabditis elegans.
AID660781Solubility of the compound in water2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Antitumor agents. 289. Design, synthesis, and anti-breast cancer activity in vivo of 4-amino-2H-benzo[h]chromen-2-one and 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogues with improved water solubility.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID420670Inhibition of mouse CYP2A52009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
AID1386829Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 72 hrs by cell-QB reagent based assay2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.
AID241174Inhibitory concentration against mouse cytochrome P450 2A52005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID513047Inhibition of human caspase-3-mediated apoptosis assessed as appearance of [35]S methionine-labeled PARP cleavage product at 100 uM after 2 hrs by fluorescence assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
The nongenotoxic carcinogens naphthalene and para-dichlorobenzene suppress apoptosis in Caenorhabditis elegans.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
AID420671Inhibition of human CYP2A62009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques.
AID242975Ratio of IC50 for human CYP2A6 to that of mouse CYP2A5 was determined2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
AID1222389Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID390576Inhibition of human recombinant MK2 expressed in Escherichia coli BL21(DE3) after 60 mins2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.
AID636076Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID636075Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis, biological evaluation and mechanistic studies of totarol amino alcohol derivatives as potential antimalarial agents.
AID6790Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
AID1799876Thermal Denaturation Assay from Article 10.1002/cbic.201200521: \\Using a fragment-based approach to target protein-protein interactions.\\2013Chembiochem : a European journal of chemical biology, Feb-11, Volume: 14, Issue:3
Using a fragment-based approach to target protein-protein interactions.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013Chembiochem : a European journal of chemical biology, Feb-11, Volume: 14, Issue:3
Using a fragment-based approach to target protein-protein interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (451)

TimeframeStudies, This Drug (%)All Drugs %
pre-199099 (21.95)18.7374
1990's83 (18.40)18.2507
2000's112 (24.83)29.6817
2010's125 (27.72)24.3611
2020's32 (7.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.00 (24.57)
Research Supply Index6.16 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index103.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.21%)5.53%
Reviews3 (0.64%)6.00%
Case Studies2 (0.42%)4.05%
Observational0 (0.00%)0.25%
Other465 (98.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]